Schoeller Allibert contributes in the global battle against Covid-19
Hoofddorp | Feb. 2021
Schoeller Allibert contributes in the global battle against Covid.19 with CG Chemikalien GmbH & Co. KG
SCHOELLER ALLIBERT CONTRIBUTES IN THE GLOBAL BATTLE AGAINST COVID-19 WITH CG Chemikalien GmbH & Co. KG
When scientists began seeking a vaccine in early 2020, they were very careful in communicating a possible delivery date. The development of a vaccine is something that cannot be rushed and the fastest any vaccine had previously been developed from sample to approved vaccine, was 4 years.
The future of vaccine science has been changed thanks to the COVID-19 experience. Early December 2020 the first pharmaceutical companies, requested approval for the first fully tested immunization for emergency use.
The official first emergency use authorization (EUA) for a COVID-19 vaccine was given on December 11, 2020. This authorization allows the distribution in the U.S. The EMA (European Medicines Agency) followed by recommending it for authorization in the EU on Dember 21; 2020. The next challenge lies now to produce it in massive quantities to supply it on a global level.